Company news
Aptorum Group Limited news in 2022
Aptorum Group Limited's news releases, calls and decks from 2022, newest first.
Aptorum Group Limited Announces Results of 2022 Annual General Meeting of Shareholders
December 21, 2022
Aptorum Group Announces Completion of $3 Million Convertible Note due 2023
December 15, 2022
Aptorum Group Announces Offering of $3 Million Convertible Note due 2023
December 8, 2022
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 21, 2022
November 7, 2022
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2022
September 29, 2022
Aptorum Group Launches NativusWell®, a Novel Nutraceutical for Menopause, in Hong Kong
September 14, 2022
Aptorum Group Updates on Data from the Completed Phase 1 Clinical Trial of SACT-1, targeting neuroblastoma
May 1, 2022
Aptorum Group Limited Reports 2021 Fiscal Year End Financial Results and Provides Business Update
April 28, 2022
Aptorum Group Receives FDA Orphan Drug Designation for its SACT-1 Repurposed Drug For The Treatment of Neuroblastoma
January 19, 2022
Aptorum Group Announces Updates on the Clinical Validation of its RPIDD Infectious Disease Liquid Biopsy Technology
January 9, 2022
Aptorum Group Announces the Launch of its Oncology and Autoimmune Discovery and Development Platform Targeting Unmet Mutations and Novel Biomarkers
January 9, 2022
Aptorum Group Announces Completion of Phase I Clinical Trials for ALS-4 and SACT-1, Small Molecule Drugs Targeted for Infections Caused by Staphylococcus Aureus and Neuroblastoma
January 9, 2022